Inactivation of p53 Rescues the Maintenance of High Risk HPV DNA Genomes Deficient in Expression of E6

PLoS Pathogens

Volumn 9, Issue 10, 2013, Pages

  Lorenz, Laurel D ^a   Rivera Cardona, Jessenia ^a   Lambert, Paul F ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN; PROTEIN E6; PROTEIN P53; VIRUS DNA;

ARTICLE; CONTROLLED STUDY; GENE INACTIVATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; KERATINOCYTE; NONHUMAN; PDZ DOMAIN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; VIRUS GENOME;

ALPHAPAPILLOMAVIRUS; CELL LINE, TRANSFORMED; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, VIRAL; GENOME, VIRAL; HUMANS; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION;

EID: 84887302583     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003717     Document Type: Article

References (89)

1. Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF, (2009) Establishment of human papillomavirus infection requires cell cycle progression. PLoS pathogens 5: e1000318.
2. Peh WL, Middleton K, Christensen N, Nicholls P, Egawa K, et al. (2002) Life cycle heterogeneity in animal models of human papillomavirus-associated disease. Journal of virology 76: 10401-10416.
3. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, et al. (2012) The biology and life-cycle of human papillomaviruses. Vaccine 30 Suppl 5: F55-70.
4. Meyers C, Mayer TJ, Ozbun MA, (1997) Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. Journal of virology 71: 7381-7386.
5. Flores ER, Allen-Hoffmann BL, Lee D, Sattler CA, Lambert PF, (1999) Establishment of the human papillomavirus type 16 (HPV-16) life cycle in an immortalized human foreskin keratinocyte cell line. Virology 262: 344.
6. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of pathology 189: 12-19.
7. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, et al. (2009) A review of human carcinogens-Part B: biological agents. The lancet oncology 10: 321-322.
8. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. The New England journal of medicine 348: 518-527.
9. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, et al. (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. Journal of the National Cancer Institute 87: 796-802.
10. Parkin DM, (2006) The global health burden of infection-associated cancers in the year 2002. International journal of cancer Journal international du cancer 118: 3030-3044.
11. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, et al. (2005) The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337: 76-84.
12. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, et al. (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA: the journal of the American Medical Association 298: 743-753.
13. McBride AA, (2008) Replication and partitioning of papillomavirus genomes. Advances in virus research 72: 155-205.
14. Lusky M, Botchan MR, (1986) Transient replication of bovine papilloma virus type 1 plasmids: cis and trans requirements. Proceedings of the National Academy of Sciences of the United States of America 83: 3609-3613.
15. Chiang CM, Ustav M, Stenlund A, Ho TF, Broker TR, et al. (1992) Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins. Proceedings of the National Academy of Sciences of the United States of America 89: 5799-5803.
16. Del Vecchio AM, Romanczuk H, Howley PM, Baker CC, (1992) Transient replication of human papillomavirus DNAs. J Virol 66: 5949-5958.
17. Ustav M, Stenlund A, (1991) Transient replication of BPV-1 requires two viral polypeptides encoded by the E1 and E2 open reading frames. EMBO J 10: 449-457.
18. Bedell MA, Hudson JB, Golub TR, Turyk ME, Hosken M, et al. (1991) Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. Journal of virology 65: 2254-2260.
19. Stanley MA, Browne HM, Appleby M, Minson AC, (1989) Properties of a non-tumorigenic human cervical keratinocyte cell line. International journal of cancer Journal international du cancer 43: 672-676.
20. Frattini MG, Lim HB, Doorbar J, Laimins LA, (1997) Induction of human papillomavirus type 18 late gene expression and genomic amplification in organotypic cultures from transfected DNA templates. Journal of virology 71: 7068-7072.
21. Oh ST, Longworth MS, Laimins LA, (2004) Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. Journal of virology 78: 2620.
22. Flores ER, Allen-Hoffmann BL, Lee D, Lambert PF, (2000) The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. Journal of virology 74: 6622.
23. Thomas JT, Hubert WG, Ruesch MN, Laimins LA, (1999) Human papillomavirus type 31 oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life cycle in normal human keratinocytes. Proceedings of the National Academy of Sciences of the United States of America 96: 8449.
24. McLaughlin-Drubin ME, Bromberg-White JL, Meyers C, (2005) The role of the human papillomavirus type 18 E7 oncoprotein during the complete viral life cycle. Virology 338: 61.
25. Fang L, Budgeon LR, Doorbar J, Briggs ER, Howett MK, (2006) The human papillomavirus type 11 E1∧E4 protein is not essential for viral genome amplification. Virology 351: 271-279.
26. Nakahara T, Peh WL, Doorbar J, Lee D, Lambert PF, (2005) Human papillomavirus type 16 E1circumflexE4 contributes to multiple facets of the papillomavirus life cycle. Journal of virology 79: 13150.
27. Wilson R, Fehrmann F, Laimins LA, (2005) Role of the E1-E4 protein in the differentiation-dependent life cycle of human papillomavirus type 31. Journal of virology 79: 6732-6740.
28. Wilson R, Ryan GB, Knight GL, Laimins LA, Roberts S, (2007) The full-length E1E4 protein of human papillomavirus type 18 modulates differentiation-dependent viral DNA amplification and late gene expression. Virology 362: 453-460.
29. Egawa N, Nakahara T, Ohno S, Narisawa-Saito M, Yugawa T, et al. (2012) The E1 protein of human papillomavirus type 16 is dispensable for maintenance replication of the viral genome. Journal of virology 86: 3276-3283.
30. Kim K, Lambert PF, (2002) E1 protein of bovine papillomavirus 1 is not required for the maintenance of viral plasmid DNA replication. Virology 293: 10-14.
31. Wang H-K, Duffy AA, Broker TR, Chow LT, (2009) Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes & development 23: 181-194.
32. Kho EY, Wang HK, Banerjee NS, Broker TR, Chow LT, (2013) HPV-18 E6 mutants reveal p53 modulation of viral DNA amplification in organotypic cultures. Proceedings of the National Academy of Sciences of the United States of America 110: 7542-7549.
33. Genther SM, Sterling S, Duensing S, Munger K, Sattler C, et al. (2003) Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. Journal of virology 77: 2832.
34. Seedorf K, Oltersdorf T, Krammer G, Rowekamp W, (1987) Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. The EMBO journal 6: 139-144.
35. Smotkin D, Wettstein FO, (1986) Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proceedings of the National Academy of Sciences of the United States of America 83: 4680.
36. Smotkin D, Prokoph H, Wettstein FO, (1989) Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. The Journal of Virology 63: 1441.
37. Kanda T, Watanabe S, Zanma S, Sato H, Furuno A, et al. (1991) Human papillomavirus type 16 E6 proteins with glycine substitution for cysteine in the metal-binding motif. Virology 185: 536-543.
38. Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T, et al. (1997) Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proceedings of the National Academy of Sciences of the United States of America 94: 11612.
39. Nakagawa S, Huibregtse JM, (2000) Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Molecular and cellular biology 20: 8244.
40. Cole ST, Danos O, (1987) Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. Journal of molecular biology 193: 599-608.
41. Barbosa MS, Lowy DR, Schiller JT, (1989) Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. Journal of virology 63: 1404-1407.
42. Howie HL, Katzenellenbogen RA, Galloway DA, (2009) Papillomavirus E6 proteins. Virology 384: 324.
43. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM, (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129.
44. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM, (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495-505.
45. Huibregtse JM, Scheffner M, Howley PM, (1991) A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. The EMBO journal 10: 4129-4135.
46. Crook T, Tidy JA, Vousden KH, (1991) Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67: 547.
47. Park RB, Androphy EJ, (2002) Genetic analysis of high-risk e6 in episomal maintenance of human papillomavirus genomes in primary human keratinocytes. Journal of virology 76: 11359.
48. Liu Y, Chen JJ, Gao Q, Dalal S, Hong Y, et al. (1999) Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. Journal of virology 73: 7297.
49. Lee C, Wooldridge TR, Laimins LA, (2007) Analysis of the roles of E6 binding to E6TP1 and nuclear localization in the human papillomavirus type 31 life cycle. Virology 358: 201.
50. Allen-Hoffmann BL, Schlosser SJ, Ivarie CA, Sattler CA, Meisner LF, et al. (2000) Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. The Journal of investigative dermatology 114: 444.
51. Lambert PF, Ozbun MA, Collins A, Holmgren S, Lee D, et al. (2005) Using an immortalized cell line to study the HPV life cycle in organotypic "raft" cultures. Methods in molecular medicine 119: 141-155.
52. Mietz JA, Unger T, Huibregtse JM, Howley PM, (1992) The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. The EMBO journal 11: 5013.
53. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, et al. (1998) Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396: 84.
54. Klingelhutz AJ, Foster SA, McDougall JK, (1996) Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380: 79.
55. Foster SA, Demers GW, Etscheid BG, Galloway DA, (1994) The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. Journal of virology 68: 5698.
56. Hebner C, Beglin M, Laimins LA, (2007) Human papillomavirus E6 proteins mediate resistance to interferon-induced growth arrest through inhibition of p53 acetylation. Journal of virology 81: 12740.
57. Gilkes DM, Chen L, Chen J, (2006) MDMX regulation of p53 response to ribosomal stress. The EMBO journal 25: 5614-5625.
58. Bates S, Hickman ES, Vousden KH, (1999) Reversal of p53-induced cell-cycle arrest. Molecular carcinogenesis 24: 7-14.
59. Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, et al. (1993) Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proceedings of the National Academy of Sciences of the United States of America 90: 3988-3992.
60. Shaulian E, Zauberman A, Ginsberg D, Oren M, (1992) Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Molecular and cellular biology 12: 5581.
61. Gottlieb E, Haffner R, von Ruden T, Wagner EF, Oren M, (1994) Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. The EMBO journal 13: 1368-1374.
62. Smart P, Lane EB, Lane DP, Midgley C, Vojtesek B, et al. (1999) Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene 18: 7378-7386.
63. Shaulian E, Haviv I, Shaul Y, Oren M, (1995) Transcriptional repression by the C-terminal domain of p53. Oncogene 10: 671-680.
64. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, et al. (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes & development 12: 2831-2841.
65. Nicolaides L, Davy C, Raj K, Kranjec C, Banks L, et al. (2011) Stabilization of HPV16 E6 protein by PDZ proteins, and potential implications for genome maintenance. Virology 414: 137-145.
66. Lepik D, Ilves I, Kristjuhan A, Maimets T, Ustav M, (1998) p53 protein is a suppressor of papillomavirus DNA amplificational replication. Journal of virology 72: 6822-6831.
67. Massimi P, Pim D, Bertoli C, Bouvard V, Banks L, (1999) Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene 18: 7748-7754.
68. Brown C, Kowalczyk AM, Taylor ER, Morgan IM, Gaston K, (2008) P53 represses human papillomavirus type 16 DNA replication via the viral E2 protein. Virology journal 5: 5.
69. Ilves I, Kivi S, Ustav M, (1999) Long-term episomal maintenance of bovine papillomavirus type 1 plasmids is determined by attachment to host chromosomes, which Is mediated by the viral E2 protein and its binding sites. Journal of virology 73: 4404.
70. Desaintes C, Hallez S, Van Alphen P, Burny A, (1992) Transcriptional activation of several heterologous promoters by the E6 protein of human papillomavirus type 16. Journal of virology 66: 325-333.
71. Shirasawa H, Jin MH, Shimizu K, Akutsu N, Shino Y, et al. (1994) Transcription-modulatory activity of full-length E6 and E6*I proteins of human papillomavirus type 16. Virology 203: 36-42.
72. Reinson T, Toots M, Kadaja M, Pipitch R, Allik M, et al. (2013) Engagement of the ATR-dependent DNA damage response at the human papillomavirus 18 replication centers during the initial amplification. Journal of virology 87: 951-964.
73. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM, (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. The Journal of biological chemistry 273: 5858-5868.
74. Rogakou EP, Boon C, Redon C, Bonner WM, (1999) Megabase chromatin domains involved in DNA double-strand breaks in vivo. The Journal of cell biology 146: 905-916.
75. Sedelnikova OA, Rogakou EP, Panyutin IG, Bonner WM, (2002) Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody. Radiation research 158: 486-492.
76. Gillespie KA, Mehta KP, Laimins LA, Moody CA, (2012) Human papillomaviruses recruit cellular DNA repair and homologous recombination factors to viral replication centers. Journal of virology 86: 9520-9526.
77. Sakakibara N, Mitra R, McBride AA, (2011) The papillomavirus E1 helicase activates a cellular DNA damage response in viral replication foci. Journal of virology 85: 8981-8995.
78. Lakin ND, Jackson SP, (1999) Regulation of p53 in response to DNA damage. Oncogene 18: 7644-7655.
79. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, et al. (2003) Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424: 516-523.
80. Munoz-Fontela C, Macip S, Martinez-Sobrido L, Brown L, Ashour J, et al. (2008) Transcriptional role of p53 in interferon-mediated antiviral immunity. The Journal of experimental medicine 205: 1929-1938.
81. Pett MR, Herdman MT, Palmer RD, Yeo GS, Shivji MK, et al. (2006) Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. Proceedings of the National Academy of Sciences of the United States of America 103: 3822-3827.
82. Turek LP, Byrne JC, Lowy DR, Dvoretzky I, Friedman RM, et al. (1982) Interferon induces morphologic reversion with elimination of extrachromosomal viral genomes in bovine papillomavirus-transformed mouse cells. Proceedings of the National Academy of Sciences of the United States of America 79: 7914-7918.
83. Chang YE, Pena L, Sen GC, Park JK, Laimins LA, (2002) Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. Journal of virology 76: 8864-8874.
84. Herdman MT, Pett MR, Roberts I, Alazawi WO, Teschendorff AE, et al. (2006) Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis 27: 2341-2353.
85. Chang YE, Laimins LA, (2000) Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. Journal of virology 74: 4174-4182.
86. Reiser J, Hurst J, Voges M, Krauss P, Munch P, et al. (2011) High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. Journal of virology 85: 11372-11380.
87. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, et al. (2001) Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. Journal of virology 75: 4283-4296.
88. Moiseeva O, Mallette FA, Mukhopadhyay UK, Moores A, Ferbeyre G, (2006) DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation. Molecular biology of the cell 17: 1583.
89. Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS, et al. (2004) STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. The Journal of biological chemistry 279: 5811-5820.